Data from the phase 3 eXalt3 trial support the approval of ensartinib in adult patients with metastatic ALK-positive non–small cell lung cancer.
Approval Alert | Ensartinib in Metastatic ALK-Positive NSCLC
Advertisement
Advertisement
Trending on CancerNetwork
1
Modifiable Risk Factors Suggest Potential for Improving Cancer Prevention
2
2026 Tandem Meetings: What’s the Latest Research in Multiple Myeloma?
3
Dato-DXd Receives Priority Review in Unresectable/Metastatic TNBC
4
Barriers to CAR T-Cell Referral and Center Access in Multiple Myeloma
5